Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum.
about
Huntington's disease: the past, present, and future search for disease modifiers.Characterization of HTT inclusion size, location, and timing in the zQ175 mouse model of Huntington's disease: an in vivo high-content imaging studyHuntingtin is required for normal excitatory synapse development in cortical and striatal circuitsA fully humanized transgenic mouse model of Huntington disease.Allele-Selective Suppression of Mutant Huntingtin in Primary Human Blood Cells.Preclinical Evaluation of a Lentiviral Vector for Huntingtin Silencing.Oligonucleotide-based strategies to combat polyglutamine diseases.Targets for future clinical trials in Huntington's disease: what's in the pipeline?Phosphorodiamidate morpholino oligomers suppress mutant huntingtin expression and attenuate neurotoxicity.Broad distribution of ataxin 1 silencing in rhesus cerebella for spinocerebellar ataxia type 1 therapy.Gene suppression strategies for dominantly inherited neurodegenerative diseases: lessons from Huntington's disease and spinocerebellar ataxia.Transcription, epigenetics and ameliorative strategies in Huntington's Disease: a genome-wide perspectiveA striatal-enriched intronic GPCR modulates huntingtin levels and toxicityOnset Time and Durability of Huntingtin Suppression in Rhesus Putamen After Direct Infusion of Antihuntingtin siRNA.Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice.Mechanism of allele-selective inhibition of huntingtin expression by duplex RNAs that target CAG repeats: function through the RNAi pathwayTranslational research in Huntington's disease: opening up for disease modifying treatmentRecent advances in RNA interference therapeutics for CNS diseases.Bidirectional control of postsynaptic density-95 (PSD-95) clustering by Huntingtin.Novel siRNA delivery strategy: a new "strand" in CNS translational medicine?Pharmacological protein targets in polyglutamine diseases: mutant polypeptides and their interactors.Use of genetically modified mesenchymal stem cells to treat neurodegenerative diseases.Promising Targets for the Treatment of Neurodegenerative Diseases.AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington's disease.Stacking up CRISPR against RNAi for therapeutic gene inhibition.Huntington's Disease: Mechanisms of Pathogenesis and Therapeutic Strategies.Identification of NUB1 as a suppressor of mutant Huntington toxicity via enhanced protein clearance.Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington's disease.Design, Characterization, and Lead Selection of Therapeutic miRNAs Targeting Huntingtin for Development of Gene Therapy for Huntington's Disease.In vivo evaluation of candidate allele-specific mutant huntingtin gene silencing antisense oligonucleotides.Elimination of huntingtin in the adult mouse leads to progressive behavioral deficits, bilateral thalamic calcification, and altered brain iron homeostasis.Knockdown and replacement therapy mediated by artificial mirtrons in spinocerebellar ataxia 7.CTG repeat-targeting oligonucleotides for down-regulating Huntingtin expression.Gene suppression approaches to neurodegeneration.Stereotaxic Surgical Targeting of the Nonhuman Primate Caudate and Putamen: Gene Therapy for Huntington's Disease.Therapies targeting DNA and RNA in Huntington's disease.Suppression of MAPK11 or HIPK3 reduces mutant Huntingtin levels in Huntington's disease models.Emerging Diagnostic and Therapeutic Strategies for Tauopathies.Effect of early embryonic deletion of huntingtin from pyramidal neurons on the development and long-term survival of neurons in cerebral cortex and striatum.Translation of MicroRNA-Based Huntingtin-Lowering Therapies from Preclinical Studies to the Clinic.
P2860
Q26830039-4CB797F3-1A7B-499D-93D3-A0981315B864Q28546047-16F5A658-00AF-4703-B7CD-E4876B0F555DQ30408636-0B49742E-1896-4AFA-AC5E-3EF0E5AF44BBQ30537951-5FC8C10C-5E0E-4273-9442-AEB85EDF0AFDQ33594270-0C1E25E0-1F8D-45C8-8793-9358D1278057Q33752590-A0492161-56D9-437E-9C24-AE928078430DQ33791247-B9C5AB89-D56A-4F6C-9EFC-4FF26798C274Q34435001-5C6A259D-DE00-4D4E-AE6A-8B92CC196277Q34463222-8B34E654-A8A2-4E63-8E18-ABBFE6D63AE2Q34498957-AB4F7A37-D03F-4516-9103-3D1C1D24E464Q34499502-674F7036-6574-423B-844F-16FC956C3021Q35024695-3363B280-11FE-401F-9AE8-710CD658E707Q35214858-D8BDE338-2FE2-49D7-A82E-B0660FE8FFC6Q36033056-020FF2D7-A49E-4B59-A5F0-28EDB4E9FFA7Q36389503-1A204C19-A4FB-4BE2-A1C8-A75DD0B81ED8Q36477988-4CD6F85A-9612-44C6-BCC1-EBC649B58AA6Q36722683-261D5D00-DC60-4907-ABC4-78B0416AC8BCQ36983193-7DB5D838-7B90-4000-A6BC-FE3F5F158514Q37563493-E9AF5D8B-2BDF-467D-8DF6-57147536D2E3Q38091009-BF11E685-10D1-42C0-826B-31E0B617EC87Q38107677-1FCA2495-CB48-4CF3-A8C2-A62ACA19675EQ38181868-A0600D00-ED45-4990-BCFA-26086AE24D80Q38562084-AC8A3917-448C-43AB-95F7-2C355BDC861BQ38644645-9482593D-C260-4704-8D3B-E596099B0B19Q38811165-CB377DEB-569D-47F0-BC2C-E399E19E99E0Q39035495-C6429394-CFA9-4561-AB4D-74988402DC2FQ39176432-EC9BDBEF-B129-4747-88B7-6E2B2496A41DQ39795092-85E74D42-86D9-40A0-8E71-C6CE1674A0E2Q39898083-78292F65-D1D2-457A-8458-61016BA7DC43Q40609867-B43679FA-C0B6-495D-BC67-E550F50A1785Q41187089-CB6EFC67-9C09-4CEB-A8E7-D255FC377CBBQ41508524-AD201E30-C2A6-4728-B95F-6BA390263AF9Q42258984-84FE41DC-23B0-4BAD-895D-CA787E840A26Q42371261-60F91D7B-BBA8-4E7D-9323-7E478F0468E7Q45291523-CD060A66-9E59-4C6F-8B7A-3FB387D81068Q45304275-FAC0617F-DBEB-4662-BBDB-936B8FCCC86CQ45305579-A41EAA4C-01B6-4245-8CEC-7AE654514E04Q45870549-6CA3B863-5BD7-4A28-B6A3-D36B7FC7C596Q47897782-5C8A38E6-D42E-4DE3-A241-C92DDCD75482Q54262475-D64EDDD3-02DE-4C8C-AA9A-3CC627354EC6
P2860
Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Six-month partial suppression ...... in the adult rhesus striatum.
@ast
Six-month partial suppression ...... in the adult rhesus striatum.
@en
type
label
Six-month partial suppression ...... in the adult rhesus striatum.
@ast
Six-month partial suppression ...... in the adult rhesus striatum.
@en
prefLabel
Six-month partial suppression ...... in the adult rhesus striatum.
@ast
Six-month partial suppression ...... in the adult rhesus striatum.
@en
P2093
P2860
P356
P1433
P1476
Six-month partial suppression ...... in the adult rhesus striatum.
@en
P2093
Deepak R Thakker
Eric N Burright
Janelle L Blum
Jennifer Heisel
Marcy R Weatherspoon
Michael D Kaytor
Peter T Nelson
Richard Grondin
William F Kaemmerer
P2860
P304
P356
10.1093/BRAIN/AWR333
P407
P577
2012-01-16T00:00:00Z